×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: cancer | prostate | merck | keytruda | trial | discontinue | survival

Merck Ends Keytruda Prostate Cancer Trial After Found Ineffective

Merck logo on screen of tablet
(Dreamstime)

Wednesday, 25 January 2023 07:29 AM EST

Merck & Co Inc said on Wednesday it was discontinuing a late-stage trial of its blockbuster immunotherapy Keytruda in some prostate cancer patients after interim data showed it was unlikely to meet the study's main goals.

The interim analysis showed the therapy did not extend survival or help extend the time a patient lives without the disease worsening, the U.S. drugmaker said.

The drug was being tested in combination with androgen deprivation therapy and Xtandi, made by Pfizer Inc and Astellas Pharma Inc, in patients with hormone-sensitive prostate cancer that has spread to other parts of the body.

Separately, Merck said Keytruda in combination with a chemotherapy showed significant improvement in overall survival in patients with an advanced type of bile duct cancer.

The drugmaker's shares fell marginally to $107.86 in premarket trading. 

© 2023 Thomson/Reuters. All rights reserved.


Health-News
Merck & Co Inc said on Wednesday it was discontinuing a late-stage trial of its blockbuster immunotherapy Keytruda in some prostate cancer patients after interim data showed it was unlikely to meet the study's main goals. The interim analysis showed the therapy did not...
cancer, prostate, merck, keytruda, trial, discontinue, survival, bile
133
2023-29-25
Wednesday, 25 January 2023 07:29 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved